Abstract:Although many researchers of Parkinson's disease (PD) have shifted their focus from the central nervous system (CNS) to the peripheral blood, a significant knowledge gap remains between PD severity and the peripheral immune response. In the current study, we aimed to map the peripheral immunity atlas in peripheral blood mononuclear cells (PBMCs) from PD patients and healthy controls using single-cell RNA sequencing (scRNA-seq). Our study employed scRNA-seq analysis to map the peripheral immunity atlas in PD by profiling PBMCs from PD-Early, PD-Late patients and matched controls. By enlarging the blood sample size, we validated the roles of NK cells in numerous immune-related biological processes. We also detected the infiltration of NK cells into the cerebral motor cortex as the disease progressed, using human brain sections, and elucidated the communication between the periphery and CNS and its implications for PD. As a result, cell subpopulation atlases in PBMCs from PD patients and healthy controls along with differentially expressed genes in NK cells were identified by scRNA-seq analysis, representing 6 major immune cell subsets among which NK cells declined in the progression of PD. We further validated NK cell reduction in increasing samples and found that they participated in numerous immune-related biological processes and infiltration into the cerebral motor cortex as the disease proceeded, evidencingd the close communication between the peripheral immune response and CNS. Strikingly, XCL2 positively correlated with PD severity, with good predictive performance of PD and specific expression in subclusters C2 and C5 of NK cells. All these findings delineated the critical role of peripheral immune response mediated by NK cells in the pathogenesis of PD. NK cell-specific XCL2 could be used as a diagnostic marker for treating PD. The indispensable function of NK cells and NK cell-specific molecular biomarkers highlighted the implication of the peripheral immune response in PD progression. Trial registration: ChiCTR, ChiCTR1900023975. Registered 20 June 2019 - Retrospectively registered, https://www.chictr.org.cn/showproj.html?proj=31035 .

Verification of Expressions of Kir2 As Potential Peripheral Biomarkers in Lymphocytes from Patients with Parkinson's Disease

Identification of PLOD3 and LRRN3 as potential biomarkers for Parkinson’s disease based on integrative analysis

Single-cell RNA sequencing reveals peripheral immunological features in Parkinson's Disease

Molecular Features of Parkinson's Disease in Patient‐Derived Midbrain Dopaminergic Neurons

Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson's Disease.

Th1/Th2 Type Cytokine Gene Expression in the Peripheral Blood of Patients with Parkinson Disease

Identification of Hub Genes And Potential Molecular Mechanisms In Peripheral Blood Mononuclear Cells of Patients With Parkinson’s Disease

Integrative analysis of gene expression profiles of substantia nigra identifies potential diagnosis biomarkers in Parkinson's disease

Cytokine and Chemokine Map of Peripheral Specific Immune Cell Subsets in Parkinson's Disease

Identification and validation of key molecules associated with humoral immune modulation in Parkinson’s disease based on bioinformatics

Abnormal Subpopulations of Peripheral Blood Lymphocytes Are Involved in Parkinson's Disease

Identification of SV2C and DENR as Key Biomarkers for Parkinson's Disease Based on Bioinformatics, Machine Learning, and Experimental Verification

The role of peripheral inflammation-related biomarkers in distinguishing Parkinson's disease

Evaluation of ST13 and BCL11B Gene Expression Levels in Early Diagnosis of Parkinson's Disease

Altered Expression Levels of MicroRNA-132 and Nurr1 in Peripheral Blood of Parkinson's Disease: Potential Disease Biomarkers

Analysis of Expression of the GRIPAP1, DLG4, KIF1B, NGFRAP1, and NRF1 Genes in Peripheral Blood of the Patients with Parkinson's Disease in the Early Clinical Stages

Analysis of LRRN3, MEF2C, SLC22A, and P2RY12 Gene Expression in the Peripheral Blood of Patients in the Early Stages of Parkinson's Disease

Distinctive CD56dim NK subset profiles and increased NKG2D expression in blood NK cells of Parkinson’s disease patients

Low-variance RNAs Identify Parkinson's Disease Molecular Signature in Blood.

Identification of Distinct Blood-Based Biomarkers in Early Stage of Parkinson’s Disease

Expressions of CD14 mRNA and TLR4 mRNA in peripheral blood mononuclear cells in patients with Parkinson disease